特异性
phospho-KDR/VEGFR2 (Tyr1214)
免疫原
(...FHpYDN...) in which pY corresponds to phosphorylated tyrosine at residue 1214 of human KDR/VEGFR2. Tyr1214 of human KDR corresponds to Tyr1212 in the mouse protein.
应用
Anti-phospho-KDR/Flk-1/VEGFR2 (Tyr1214) Antibody detects level of phospho-KDR/Flk-1/VEGFR2 (Tyr1214) & has been published & validated for use in WB.
Research Category
Signaling
Signaling
Research Sub Category
Growth Factors & Receptors
Growth Factors & Receptors
质量
routinely evaluated by immunoblot RIPA lysates from porcine aortic endothelial cells expressing human CSF-1R/murineVEGFR-2 chimera
目标描述
200-230 kDa
外形
Protein A purified
0.1M Tris-glycine, pH 7.4, 0.15M NaCl,0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
储存及稳定性
2 years at -20°C
法律信息
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
WGK 1
V Dayanir et al.
The Journal of biological chemistry, 276(21), 17686-17692 (2001-03-30)
Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in vasculogenesis and angiogenesis. However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular
Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation.
Meyer, Rosana D, et al.
Oncogene, 23, 5523-5531 (2004)
Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.
Dellinger, MT; Brekken, RA
Testing null
Michael J Donovan et al.
European journal of cancer (Oxford, England : 1990), 45(8), 1518-1526 (2009-03-11)
To identify clinical and biometric features associated with overall survival of patients with advanced refractory non-small-cell lung cancer (NSCLC) treated with gefitinib. One hundred and nine diagnostic NSCLC samples were analysed for EGFR mutation status, EGFR immunohistochemistry, histologic morphometry and
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Albert, DH; Tapang, P; Magoc, TJ; Pease, LJ; Reuter, DR; Wei, RQ; Li, J; Guo, J; Bousquet et al.
Molecular Cancer Therapeutics null
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门